ΑMT
From PsychonautWiki
(Redirected from Alpha-Methyltryptamine)
Jump to: navigation, search
ΑMT
AMT2.png
Chemical Nomenclature
Common names AMT, αMT, Indopan
Substitutive name α-Methyltryptamine
Systematic name 2-(1H-indol-3-yl)-1-methyl-ethylamine
Routes of Administration


Oral
Dosage
Presumes no tolerance
Threshold 5 - 15mg
Light 10 - 25mg
Common 20 - 40mg
Strong 30 - 60mg
Heavy 60 - 80mg
Duration
Total 13 - 15 hours
Onset 60 - 180 mins
Peak 4 - 6 hours
Afterglow 1 - 5 hours









α-Methyltryptamine (αMT, AMT, Indopan) is a psychedelic, stimulant, and entactogen drug of the tryptamine class.[1] It was originally developed as an antidepressant by workers at a Michigan pharmaceutical manufacturing company known as Upjohn in the 1960s.[2]

The physical effects of this drug may be overly intense for those who are not already experienced with psychedelics.

Chemistry

General formula of a tryptamine molecule.

AMT is closely related to serotonin. It is made up of a tryptamine backbone and one methyl group substituted onto the monoamine chain at carbon Rα.

Pharmacology

AMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist.

AMT also acts as a releasing agent of serotonin, noradrenaline, and dopamine.[3][4] It also acts as a very weak, non-selective RIMA in-vitro[5] and in-vivo.[6], but this is unlikely to be very significant (if at all) with typical doses.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely if ever occur all at once but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

The physical effects of AMT can be broken down into several components all of which progressively intensify proportional to dosage. These are described below and generally include:

  • Spontaneous tactile sensations - AMT's "body high" can be described as an intense and constant all-encompassing sensation. In comparison to other psychedelics, this sensation does not manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body spontaneously; it is instead felt as an extended, unchanging activation of every nerve ending on the body that lasts throughout the entire duration of the trip. This continuous sensation is immensely pleasurable but can become overwhelmingly intense and almost a burden at higher levels.
  • Stimulation - In terms of its effects on the physical energy levels of the tripper, AMT is very stimulating, resulting in jaw clenching and a shakiness and unsteadiness of the hands. The stimulation encourages trippers to move around, run, dance, climb or generally engage in physical activities. In comparison, other more commonly used psychedelics such as psilocybin are generally sedating and relaxed.
  • Nausea - In terms of the physical discomfort experienced on this substance, moderate to extreme nausea is almost consistently reported when consumed at any dosage. This either passes once the tripper has vomited or gradually fades by itself as the peak sets in.
  • Difficulty urinating - A slight difficulty urinating is occasionally present.
  • Headaches - Many people report headaches towards the end of the experience
  • Temperature regulation loss
  • Increased heart rate
  • Pupil dilation

Cognitive effects

In comparison to more traditional psychedelics such as LSD, DMT and Psilocin, the AMT head space is described as not nearly as deep, insightful or profound.

The total sum of these cognitive components regardless of the setting generally includes:

Visual effects

The visual effects of AMT are mostly present only when large doses have been consumed and are proportionally mild in comparison to the intensity of its accompanying cognitive and physical effects when compared to substances such as LSD and psilocin.

Enhancements

AMT presents a full and complete array of possible visual enhancements which generally includes:

Distortions

As for visual distortions and alterations, the effects experienced are detailed below:

Geometry

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of Psilocin and 2C-E than LSD. At lower levels it can appear to be bland and simplistic in complexity but becomes equal in terms of intricacy and depth to that of any of the classical psychedelics at higher dosages. It can be comprehensively described with its variations as intricate in complexity (at heavy dosages), abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in soft and sharp edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in depth, and consistent in intensity. At higher dosages, the visual geometry is significantly more likely to result in states of Level 8B geometry over Level 8A.

Hallucinatory states

At high dosages, AMT can produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. These effects include:

Auditory effects

The auditory effects of AMT are common in their occurrence and exhibit a full range of effects which commonly includes:

Toxicity and harm potential

Lethal dosage

The toxicity and long term health effects of recreational AMT use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because AMT is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried AMT within the psychedelic community suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).

Interactions

Deaths from AMT are rare but, as a powerful monoamine releaser, injury can occur when excessive doses are taken or when taken with drugs such as other MAOIs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.[7]

Tolerance and addiction potential

AMT use leads to approximately a week tolerance, affecting other tryptamines as well. Addiction potential has not been studied, but is considered by users to be relatively low. Like many other serotonin releasing agents, AMT's analogue αET has been shown to produce long-lasting serotonergic neurotoxicity at very high doses.[8] It is possible that AMT could cause the same neurotoxicity at high dosages or with repeated long term use.

Legal issues

  • Australia: Sale and possession of AMT is illegal.
  • Germany: Sale and possession of AMT is illegal.
  • Greece: Sale and possession of AMT is illegal.
  • Japan: Sale and possession of AMT is illegal.
  • Russia: Sale and possession of AMT is illegal.
  • Sweden: Sale and possession of AMT is illegal.[9]
  • USA: AMT is a Schedule I drug.[10]
  • UK: AMT is a class A drug and the sale and possession are illegal. See "The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014"[11]
  • Canada: Canada has no mention of this substance in the Controlled Drugs and Substances Act.[12]

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

See also

References

  1. Erowid Online Books : TIHKAL - #48 a-MT | http://www.erowid.org/library/books_online/tihkal/tihkal48.shtml
  2. US Patent 3296072 - Method of Treating Mental Depression
  3. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(06)01381-1
  4. In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes | https://www.jstage.jst.go.jp/article/bpb/30/12/30_12_2328/_article
  5. Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine | https://www.jstage.jst.go.jp/article/jphs1951/41/2/41_2_191/_article
  6. THE EFFECT OF THREE TRYPTAMINE DERIVATIVES ON SEROTONIN METABOLISM IN VITRO AND IN VIVO | http://jpet.aspetjournals.org/content/127/2/110.short
  7. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
  8. Reduction in brain serotonin markers by α-ethyltryptamine (Monase) | http://www.sciencedirect.com/science/article/pii/001429999190686K
  9. Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  10. Drug Enforcement Administration | http://webcache.googleusercontent.com/search?q=cache:http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf
  11. The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 | http://www.legislation.gov.uk/uksi/2014/3271/article/4/made
  12. CSDA | http://isomerdesign.com/Cdsa/schedule.php?structure=C